Indrayani Biotech Limited, a Chennai-based company, has taken a significant step towards strengthening its capital structure. The company announced that it has received in-principle approval from BSE Limited for a proposed rights issue of partly paid-up equity shares.

Key Details of the Approval

Company's Disclosure

The company made this announcement through a regulatory filing signed by Swaminathan G, the Whole-time Director of Indrayani Biotech Limited. The approval grants BSE's consent for the proposed rights issue under the Securities and Exchange Board of India (SEBI) listing regulations.

Additional Information

According to the LODR (Listing Obligations and Disclosure Requirements) data:

• The company officially intimated the BSE about the in-principle approval on September 20, 2025.
• The approval falls under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
• Indrayani Biotech Limited is listed on the BSE with the scrip code 526445.

About Indrayani Biotech Limited

Indrayani Biotech Limited is headquartered at Block 1, 33, SIDCO Electronic Complex, Thiru Vi Ka Industrial Estate, Guindy, Chennai 600032. The company's Corporate Identification Number (CIN) is L40100TN1992PLC129301.

This development marks a crucial step for Indrayani Biotech as it moves forward with its capital raising plans. The rights issue, once completed, could provide the company with additional funds for its business operations and growth strategies. Shareholders and potential investors are advised to keep an eye on further announcements regarding the details of the rights issue, including the issue price, rights entitlement ratio, and the timeline for subscription.

Indrayani Biotech Limited has announced a significant development in its financial services portfolio. The company's wholly-owned subsidiary, IBL Investments Limited, has successfully obtained approval from the Securities and Exchange Board of India (SEBI) for a Category II Alternative Investment Fund (AIF) registration.

Key Details of the Approval

The approval grants IBL Investments Limited the authority to operate as a SEBI-registered Category II Alternative Investment Fund. This development marks a strategic expansion of Indrayani Biotech's financial services offerings through its subsidiary.

Significance of the Approval

The Category II AIF registration is a notable achievement for IBL Investments Limited and its parent company, Indrayani Biotech. Alternative Investment Funds are privately pooled investment vehicles that collect funds from sophisticated investors, whether Indian or foreign, for investing in accordance with a defined investment policy.

Category II AIFs can invest in a wide range of strategies, including private equity, debt funds, and fund of funds. This approval opens up new avenues for IBL Investments Trust to attract investments and potentially enhance its asset management capabilities.

Regulatory Compliance

Indrayani Biotech Limited has duly informed the BSE Limited about this development, adhering to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's prompt disclosure demonstrates its commitment to transparency and regulatory compliance.

Company Background

Indrayani Biotech Limited, headquartered in Chennai, is a diversified company with interests in various sectors. The expansion into alternative investment funds through its subsidiary indicates the company's efforts to diversify its revenue streams and strengthen its position in the financial services sector.

This strategic move by Indrayani Biotech, through its subsidiary IBL Investments Limited, positions the company to capitalize on the growing alternative investment market in India.